Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 15/20 | 0.80 |
| ▸ | ROCK2 | O75116 | 15/20 | 0.80 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.80 |
| ▸ | PRKG1 | Q13976 | 9/20 | 0.80 |
| ▸ | PRKACA | P17612 | 8/20 | 0.80 |
| ▸ | PRKX | P51817 | 8/20 | 0.80 |
| ▸ | PKN2 | Q16513 | 8/20 | 0.80 |
| ▸ | PRKG2 | Q13237 | 7/20 | 0.80 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.80 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.80 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.80 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.80 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.80 |
| ▸ | GSK3B | P49841 | 9/20 | 0.79 |
| ▸ | RPS6KA5 | O75582 | 8/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.79 |
| ▸ | GSK3A | P49840 | 7/20 | 0.79 |
| ▸ | SGK2 | Q9HBY8 | 6/20 | 0.79 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102566 | 1.00 | ROCK1 (0.80) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL14949855 | 0.89 | ROCK1 (1.00) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL3104425 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL3092785 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL3106811 | 0.83 | ROCK2 (0.79) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL11582078 | 0.81 | ROCK2 (0.70) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL11581684 | 0.81 | ROCK2 (0.53) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL11582076 | 0.81 | ROCK2 (0.53) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL11582081 | 0.81 | ROCK2 (0.70) | ROCK1ROCK2CLK4PRKG1PRKACA | |
| SCHEMBL6092542 | 0.80 | ROCK2 (0.80) | ROCK1ROCK2CLK4PRKG1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903349-B | 4- (4-pyridinyl) -benzamides and their use as ROCK activity modulators | ABBOTT GMBH & CO KG | 2014-01-08 | — | — | CN | claimed |
| US-8445686-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2013-05-21 | — | — | US | claimed |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8895749-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| CN-103896831-A | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE DEUTSCHLAND | 2014-07-02 | — | — | CN | disclosed |
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8445686-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2193119-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | Abbott GmbH & Co. KG (DE) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009027392-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBOTT GMBH & CO. KG (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | ROCK1 2/4885ROCK2 3/4885CLK4 2711/4885 |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | ROCK1 2/4885ROCK2 3/4885CLK4 2723/4885 |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | ROCK1 2/4885ROCK2 3/4885CLK4 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.